Organon Acquired by Sun Pharma | Healthcare M&A Deal

Sun Pharma has acquired Organon, a pharmaceuticals business in the United States, for $11.75 billion. Sun Pharma acquisitions add Organon’s women’s health and biosimilars portfolio, with over 70 products sold across about 140 countries, supporting global manufacturing scale. Organon operates multiple manufacturing facilities across the European Union and emerging markets, strengthening Sun Pharma’s healthcare M&A capabilities and biosimilars reach. The strategic acquisition is structured as a merger acquisition and is expected to close in early 2027, subject to regulatory approvals and shareholder consent, with an all-cash offer of $14 per share for all outstanding shares.